Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease
Can-Fite BioPharma (NYSE American: CANF) reported Phase 2a results for Namodenoson in advanced pancreatic ductal adenocarcinoma. In an open-label study of 20 patients, it met the primary safety endpoint and showed durable survival in a third-line subgroup: median OS >5 months; 62.5% alive at 5 months; 37.5% at 7 months. Can-Fite plans a Phase 2b chemo-combination study.
How this was made
The 30-second read
Why it matters
If the Phase 2b combination trial is well-designed and shows improved efficacy with acceptable safety, it could materially improve CANF’s clinical probability and investor expectations; otherwise, the signal may fade quickly given the small sample size.
Market read
Traders may treat this as a catalyst-driven biotech re-rating: safety endpoint met, durable survival highlighted, and a Phase 2b combination step announced.
What to watch
The press release emphasizes safety and subgroup survival but does not provide response rates, objective tumor metrics, or statistical comparisons; Phase 2b outcomes and endpoints will be the real inflection.
Background
Namodenoson (A3 adenosine receptor agonist) is being evaluated across multiple indications; this update focuses on advanced pancreatic ductal adenocarcinoma Phase 2a results and next-step combination plans.
Ticker impact
Can-Fite reports Phase 2a Namodenoson in advanced pancreatic cancer met the primary safety endpoint and shows durable survival in a third-line subgroup.
Near-term upside bias on biotech sentiment, with follow-through dependent on Phase 2b design details and future efficacy readouts.
The release is a primary disclosure of updated survival outcomes and a planned Phase 2b combination step, which can re-rate probability-weighted outcomes, though sample size is small (20 patients) and open-label.
Market effects
Adds incremental evidence for A3 adenosine receptor agonist strategy in pancreatic cancer and supports combination-therapy rationale in oncology small molecules.
Limited; primarily impacts US-listed small-cap biotech sentiment (CANF) with potential spillover to Israeli biotech peers only if follow-on data emerges.
Moderate; pancreatic cancer remains high-interest, but this is early-stage and company-specific rather than a broad industry catalyst.
Counterpoint
Durable survival is based on a small, selected evaluable subset (8 third-line patients) in an open-label study, so efficacy signal may be overstated versus controlled trials.
Key entities
- companyCan-Fite BioPharma Ltd.
Sponsor of the Phase 2a Namodenoson study in advanced pancreatic cancer; plans Phase 2b combination with chemotherapy.
- drugNamodenoson
Small orally bioavailable A3 adenosine receptor agonist; reported primary safety endpoint achievement and durable survival in a third-line subgroup.
- clinical_trialPhase 2a study (open-label)
Enrolled 20 advanced pancreatic cancer patients; updated survival analysis in evaluable third-line patients.
